Related Experiment Videos
[Diabetic polyneuropathy treatment by milgamma-100 preparation]
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova
|October 29, 1998
Summary
Milgamma-100, a combination of benfotiamine and pyridoxine, effectively treats diabetic polyneuropathy. This treatment significantly reduced pain and improved nerve function in patients with type II diabetes.
Area of Science:
- Neurology
- Endocrinology
- Pharmacology
Background:
- Diabetic polyneuropathy is a common complication of type II diabetes.
- It significantly impacts patients' quality of life due to pain and sensory deficits.
Purpose of the Study:
- To evaluate the efficacy and safety of Milgamma-100 in treating diabetic polyneuropathy.
- To assess the impact of Milgamma-100 on pain, vibratory sensitivity, and nerve conduction.
Main Methods:
- A study involving 14 patients with type II diabetes and polyneuropathy.
- Patients received Milgamma-100 (benfotiamine 100 mg + pyridoxine 100 mg) at a dosage of 1 dragee three times daily for 6 weeks.
Main Results:
- Significant reduction in pain intensity (average VAS score from 8.2 to 2.3).
- Marked improvement in vibratory sensitivity and parasympathetic heart rhythm control.
- Shortening of evoked sympathetic potential latencies and a trend towards increased motor nerve conduction velocity.
- 93% of patients showed clinical improvement.
Conclusions:
- Milgamma-100 demonstrates significant efficacy in managing diabetic polyneuropathy symptoms.
- The preparation is safe and effective for therapeutic application in this patient group.